GLPwatch

Investigation of Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-6856 in Healthy Participants, Including a Subset of Healthy Japanese Participants

NCT06069895 · Completed

Last updated 2026-05-28

This clinical trial tests the safety, tolerability, and how the body processes multiple doses of the drug NNC0113-6856 in healthy adults, including a group of healthy Japanese participants.

Status Completed The study has finished.
Phase Phase 1 Checks safety and dosing in a small group.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 170 people
Who can join Ages 18–55 · all sexes Healthy volunteers accepted.
Timeline Started 2023-10 · est. completion 2025-04
Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT06069895 ↗

Description as written by the study sponsor.

NNC0113-6856 is a new medicine which may help participants with type 2 diabetes to improve blood sugar control. NNC0113-6856 is slowly converted in the body to semaglutide, a substance similar to a hormone (signaling substance) in the body. The main purpose of this study will be to evaluate the safety of different strengths of NNC0113-6856 when given as multiple administrations, and the amount of NNC0113-6856 in the blood will be measured as well as the amount of specific parts (including semaglutide). Participants will either get multiple doses of the new medicine NNC0113-6856 or multiple doses of placebo (a "dummy" medicine that looks like the new medicine but is without any active ingredient). Whether participants get the new medicine or placebo is decided by chance. The duration of the study could last up to 25 weeks.

Treatments tested

Main thing measuredNumber of adverse events (AEs)
SponsorNovo Nordisk A/S
Conditions studiedHealthy Participants
GLP-1 drugs —

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06069895 ↗